Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cobimetinib plus atezolizumab versus pembrolizumab in untreated advanced BRAF V600 wild-type melanoma
NL-OMON46404Phase 3Active, not recruiting
- Sponsor
- Roche
- Start
- May 2018
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in melanoma comparing Cobimetinib + atezolizumab with Pembrolizumab (2 arms). Primary endpoint: Progression-free survival. Started May 2018; status: active, not recruiting.
02
Drugs
03
Conditions
melanoma
Beyond the preview
Go deeper on NL-OMON46404.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46404.